Skip to content

Risk of Pacing-induced Cardiomyopathy

Pacing-induced Cardiomyopathy - the Importance of Right Ventricular Pacing Site and Patterns of Dyssynchronous Myocardial Activation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04269733
Enrollment
153
Registered
2020-02-17
Start date
2020-05-01
Completion date
2021-08-01
Last updated
2021-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrioventricular Block, Pacemaker DDD, Pacing-Induced Cardiomyopathy

Brief summary

This study will evaluate the association between right ventricular pacing and the risk of pacing-induced cardiomyopathy.

Detailed description

Background: Right ventricular (RV) pacing may lead to pacing-induced cardiomyopathy (PICM) and heart failure (HF). The detrimental effects of RV pacing have been attributed to the abnormal and dyssynchronous electrical and mechanical activation of the myocardium. The activation is affected by the RV pacing site. Understanding the consequences of different RV pacing sites and the patterns of dyssynchrony may help to choose the optimal treatment for the individual patient. Aim and objectives: The overall aim of this project is to investigate the association between RV pacing site and the risk of PICM. Contrast enhanced cardiac computed tomography (CT) will be applied for precise localization of the RV pacing. Furthermore, investigation of the association between PICM and different mechanical and electrical myocardial activation patterns during RV pacing will be conducted using new echocardiographic and electrocardiographic methods. Methods: The study is designed as a retrospective cohort study with clinical follow-up. Patients with prior pacemaker implantation due to advanced atrioventricular block will be included. The study baseline is retrospective and defined as time of pacemaker implantation and follow-up is time of inclusion. Baseline data will be extracted from the Danish Pacemaker- and ICD Registry, electronic medical records (EMR) and review of echocardiographs. Follow-up data will be extracted from existing data in the EMRs as well as generated during a follow-up visit with a clinical examination. For assessment of cardiac function, RV lead position and electrical and mechanical activations patterns, the examination will include a transthoracic echocardiography, an electrocardiogram, a 3-dimensional chest photo, and a contrast-enhanced cardiac CT. Data will be analysed for differences between those who develop PICM and those who do not. Expected outcomes and perspectives: The hope is that this project will generate knowledge and awareness on pacemaker treatment and the risk of PICM. Understanding the pathophysiology behind PICM is key to learning how to prevent it. Accordingly, this project has the potential to contribute to improving pacemaker treatment and the quality of care for the large and still growing PM population.

Interventions

DEVICERight ventricular pacing

Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block

Sponsors

Svend Andersens Foundation
CollaboratorUNKNOWN
Peacs
CollaboratorUNKNOWN
Aalborg University
CollaboratorOTHER
Karl G Andersens Fond
CollaboratorUNKNOWN
Sygekassernes Helsefond
CollaboratorOTHER
Aalborg University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Male or female ≥ 18 years * De novo DDD PM implanted at Aalborg University Hospital * PM implantation due to advanced AV block * Duration of pacemaker treatment ≥ 1 year at time of screening * Normal LVEF (≥50%) prior to PM implantation * Actively attending follow-up at the PM outpatient clinic at Aalborg University Hospital after PM implantation

Exclusion criteria

* No written informed consent * Baseline TTE not available or insufficient quality for assessment of LVEF * Contraindications to a new contrast CT if no previous contrast-enhanced cardiac CT, showing RV lead position, is available * RV pacing load \< 40%. * Deceased * Not attending follow-up at the PM outpatient clinic at Aalborg University Hospital after PM implantation * Device complications with removal of original implanted pacing lead \> 3 months after primary implantation * Subjects with severe ischemic heart disease and severe valvular heart disease. * Terminal illness or unable to provide informed consent at time of screening

Design outcomes

Primary

MeasureTime frameDescription
Pacing-induced cardiomyopathyAfter ≥ 1 years of exposure to right ventricular pacingTime to development of PICM. PICM is defined as ≥ 10% decrease in LVEF resulting in LVEF \< 50% after pacemaker implantation.

Secondary

MeasureTime frameDescription
Composite endpoint of new-onset heart failureAfter ≥ 1 year of exposure to right ventricular pacingHF diagnosis and/or HF hospitalization and/or Upgrading from a DDD PM to a CRT system after pacemaker implantation.
Change in LVEFAfter ≥ 1 year of exposure to right ventricular pacingChange in LVEF after pacemaker implantation.
New-onset atrial fibrillation and/or atrial flutterAfter ≥ 1 years of exposure to right ventricular pacingNew diagnosis of atrial fibrillation and/or atrial flutter after pacemaker implantation.
Change in LV end-diastolic volumeAfter ≥ 1 years of exposure to right ventricular pacingChange in LV end-diastolic volume after pacemaker implantation.
Change in LV end-systolic volumeAfter ≥ 1 years of exposure to right ventricular pacingChange in LV end-systolic volume after pacemaker implantation.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026